Unenhanced areas revealed by contrast-enhanced abdominal ultrasonography with Sonazoid™ potentially correspond to colorectal cancer.The present study investigated the potential utility of contrast-enhanced abdominal ultrasonography (CEUS), using Sonazoid™, in colorectal cancer (CRC).  Three patients were subjected to CEUS with Sonazoid™.  Prior to the administration of Sonazoid™, CRC was illustrated as irregular-shaped wall thickening.  One minute after the administration of Sonazoid™, the majority of the thickened wall was enhanced, while some parts of the thickened wall remained unenhanced.  Tumorous areas of CRC were not enhanced 1 min after the administration of Sonazoid™. 
Sonazoid
Unenhanced areas revealed by contrast-enhanced abdominal ultrasonography with Sonazoid™ potentially correspond to colorectal cancer.The present study investigated the potential utility of contrast-enhanced abdominal ultrasonography (CEUS), using Sonazoid™, in colorectal cancer (CRC). 
contrast-enhanced abdominal ultrasonography
Unenhanced areas revealed by contrast-enhanced abdominal ultrasonography with Sonazoid™ potentially correspond to colorectal cancer.The present study investigated the potential utility of contrast-enhanced abdominal ultrasonography (CEUS), using Sonazoid™, in colorectal cancer (CRC).  Three patients were subjected to CEUS with Sonazoid™.  These findings suggest that CEUS may be useful for the determination of the extent of CRC.
CEUS
Surgical specimens were immunostained for CD31.  Numbers of blood vessels positive for CD31 were analyzed in each of five fields at ×400 magnification and averaged to determine blood vessel density.  Blood vessel density was lower in tumorous areas compared with non-tumorous areas, as evidenced by immunohistochemistry for CD31. 
CD31